Heartflow, INC 8-K filings

Heartflow, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor.

Heartflow, Inc. reported robust financial results for the fourth quarter and full year ended December 31, 2025, driven by accelerating adoption of its AI technology for coronary artery disease.

Heartflow, Inc. presented robust financial performance, significant advancements in AI-powered coronary artery disease diagnostics, and strategic plans for market expansion at an investor conference.

Heartflow, Inc. announced a 41% year-over-year revenue increase in Q3 2025, alongside initiating full-year 2025 revenue guidance and highlighting key operational advancements.

Heartflow, Inc. announced preliminary unaudited financial results for Q2 2025, including revenue of $43.4 million and a gross margin of 75.5%, alongside an update on its cash position and recent IPO proceeds.

Heartflow, Inc. announced the full prepayment and termination of its Credit Agreement, settling $61.1 million in outstanding debt without incurring fees.

Heartflow, Inc. successfully closed its initial public offering, raising approximately $364 million, and simultaneously adopted new corporate governance documents.